Browsing Tag
AACR 2026
9 posts
Racura Oncology (ASX: RAC) stock up 12.21% as MYC silencing data builds case for bisantrene relaunch
MYC is the undruggable cancer gene. Racura Oncology (ASX: RAC) says bisantrene silences it via G4 stabilisation. Three clinical trials, A$19m cash, and a 2027 inflection ahead.
Why TROP2 ADC competition may hinge on payload differentiation after AKTX-101 data
Find out how AKTX-101 could reshape TROP2 ADC competition and what it means for oncology investors and strategy.
10x Genomics (TXG) just made its biggest spatial biology bet yet, can Atera change the rules?
10x Genomics has launched Atera to scale whole-transcriptome spatial biology. Read what this means for TXG, competitors, and translational research.
Why Lunit’s AACR 2026 showcase could reshape how investors value AI-driven precision oncology platforms like KRX: 328130
Lunit’s AACR 2026 studies reveal how its cancer AI platform is moving beyond pathology into biomarker strategy. Read what this means for KRX: 328130.
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
What AACR 2026 could reveal about Immunocore Holdings plc’s long-term immunotherapy durability (NASDAQ: IMCR)
Can Immunocore’s five-year KIMMTRAK data reshape oncology expectations? Discover the strategic, clinical, and investor implications now.
Antengene deepens oncology ambitions with three next-generation ADC and T-cell engager programs at AACR 2026
Discover how Antengene Corporation Limited’s AACR 2026 oncology presentations could reshape its pipeline strategy and investor outlook. Read the full analysis.